Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

58.98 -0.75 (-1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Investors should take note of NASDAQ:INCY, a growth stock that remains attractively priced.
Investors should take note ofINCYTE CORP (NASDAQ:INCY), a growth stock that remains attractively priced. 
Via Chartmill
Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness
Goldman Sachs downgraded Incyte Corp (NASDAQ: INCY), citing continued uncertainty around Jakafi (Ruxolitinib) lifecycle management ahead of the mid-27/late-28 EU/US  
Via Benzinga
The Latest Analyst Ratings for Incyte
Via Benzinga
Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents.
Investors should take notice ofINCYTE CORP (NASDAQ:INCY)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024
Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year. 
Via InvestorPlace
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
Exposures Economy
Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
Looking for growth without the hefty price tag? Consider INCYTE CORP (NASDAQ:INCY). 
Via Chartmill
Earnings Outlook For Incyte
Via Benzinga
Expert Ratings for Incyte
Via Benzinga
Goldman Sachs Maintains Buy Rating for Incyte: Here's What You Need To Know
Via Benzinga
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
From Incyte
Via Business Wire
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
From Incyte
Via Business Wire
Analyst Ratings for Incyte
Via Benzinga
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
INCYTE CORP (NASDAQ:INCY) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
From Incyte
Via Business Wire
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
From Incyte
Via Business Wire
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
From Incyte
Via Business Wire
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
From Incyte
Via Business Wire
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
From Incyte
Via Business Wire
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
From Incyte
Via Business Wire
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
From Incyte
Via Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
Pancreatic Cancer Battle Boosted by $200M VC Firm
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and... 
Via Benzinga
Exposures Product Safety
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer. 
Via Investor's Business Daily
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.